目的：探讨阿托伐他汀对不稳定型心绞痛（UAP）患者 IL-6、MMP-9及心血管事件的影响。方法将156例 UAP 患者按治疗方法的不同分为常规治疗组（78例，常规治疗＋阿托伐他汀20 mg，qn）和强化治疗组（78例，常规治疗＋阿托伐他汀40 mg，qn），连续治疗24周。在治疗前后测定2组患者的 IL-6、MMP-9水平。随访24周，观察2组患者心血管事件的发生率。结果治疗24周后，2组 IL-6、MMP-9水平较治疗前显著降低（P ＜0．05），强化治疗组的 IL-6、MMP-9降幅显著大于常规治疗组（P ＜0．05），且心血管事件发生率显著低于常规治疗组（P ＜0．05）。结论阿托伐他汀可以明显降低 UAP 患者 IL-6、MMP-9水平，减轻炎症反应，稳定冠状动脉粥样斑块，减少心血管事件的发生率。%ABSTRACT:Objective To investigate the effects of atorvastatin on interleukin-6(IL-6)and ma-trix metalloproteinase-9(MMP-9)levels and cardiovascular events in patients with unstable angi-na.Methods A total of 156 patients with unstable angina were randomly assigned to receive con-ventional therapy in combination with atorvastatin 20 mg qn(conventional treatment group,n=78)or 40 mg qn(intensive treatment group,n=78)for 24 consecutive weeks.The levels of IL-6 and MMP-9 were measured before and after treatment.In addition,the incidence of cardiovascular events was recorded during 24 weeks of follow-up.Results The levels of IL-6 and MMP-9 signif-icantly decreased after treatment for 24 weeks in both groups(P <0.05).Compared with conven-tional treatment group,levels of IL-6 and MMP-9 and incidence of cardiovascular events signifi-cantly reduced in intensive treatment group(P < 0.05).Conclusion Atorvastatin can decrease levels of IL-6 and MMP-9,attenuate inflammation,stabilize coronary atherosclerotic plaque and reduce incidence of cardiovascular events in patients with unstable angina.
展开▼
